Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + interferon alfa-2b
- Development stage
- Phase 1
- Lead developer
- Merck
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous, Intramuscular
01
Overview
Pembrolizumab + interferon alfa-2b is a combination of two immunotherapeutic agents used primarily in the treatment of advanced melanoma and other cancers. Pembrolizumab is a humanized monoclonal antibody that targets programmed cell death protein 1 (PD‑1) on T cells, blocking its interaction with PD-L1 and PD-L2, thereby enhancing the immune system’s ability to detect and destroy cancer cells. Interferon alfa‑2b is an immunomodulatory cytokine that activates immune effector cells such as CD8+ T cells, dendritic cells, and natural killer (NK) cells, while also upregulating PD-L1 expression on tumor and immune cells. The combination aims to synergistically enhance anti-tumor immunity by both priming the immune response (interferon alfa‑2b) and releasing inhibitory checkpoints (pembrolizumab). This regimen has been investigated in clinical trials for metastatic melanoma, showing promising efficacy with manageable toxicity profiles[2][5][8].
- Other names
- pegylated interferon alfa-2bPEG-IFNαrecombinant interferon alfa-2b
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on pembrolizumab + interferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + interferon alfa-2b.